Hydroxychloroquine Delays Disability For Least Treatable Form Of Multiple Sclerosis

A twice-daily dose of 200 milligram (MG) hydroxychloroquine (HCQ) tablets helped to slow the worsening of disability for people diagnosed with primary progressive multiple sclerosis (PPMS), which is considered the most difficult-to-treat form of the condition. While taking HCQ just 22.9% of participants in a small study (35 participants) experienced clinically significant worsening of PPMS over an 18-month study. At baseline before taking HCQ, about 40% of participants were expected to experience worsening disability due to PPMS.

The primary end point for determining whether the person's disability had worsened was performance on a timed . . .